We are live on ! Find out more
EcoR1 Capital

EcoR1 Capital Portfolio holdings

AUM $2.25B Turnover 39.53%
1-Year Est. Return 84.09%
 

EcoR1 Capital is a hedge fund firm that invests in biotechnology companies, mostly through their publicly traded shares. Oleg Nodelman started it after 11 years at BVF Partners, another biotech-focused hedge fund firm, where he rose from research analyst to portfolio manager, and he remains its manager and controlling owner. He named the firm after the enzyme behind DNA cloning. It buys and shorts shares, and rather than bet on the science behind a drug, it looks for companies with a margin of safety, such as patents, unreleased products or partnerships with large drug developers. A separate set of venture funds invests in privately held biotech companies around the world.

This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+84.09%
3 Year Est. Return
+357.11%
5 Year Est. Return
+437.23%
10 Year Est. Return
+11,110.7%
AUM
$2.25B
AUM Growth
+$196M
Cap. Flow
+$165M
Cap. Flow %
7.34%
Top 10 Hldgs %
83.13%
Holding
43
New
10
Increased
8
Reduced
4
Closed
7
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.2 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Miscellaneous 9.7%
3 Financials 0.23%

No holdings matched the selected filter criteria.

Similar funds

EcoR1 Capital's Q3 2026 Portfolio in Review

As of Q3 2026, EcoR1 Capital held 43 positions worth $2.25B, up 9.5% from $2.06B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

EcoR1 Capital deployed $165M of net new capital in Q3 2026, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was Alto Neuroscience: 2,232,000 shares worth $57M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Oric Pharmaceuticals, an estimated $46.1M trimmed.

  • EcoR1 Capital's largest Q3 2026 buy was Alto Neuroscience: 2,232,000 shares worth $57M.
  • EcoR1 Capital added most to Erasca in Q3 2026, an estimated $45.9M increase.
  • EcoR1 Capital's biggest Q3 2026 reduction was Oric Pharmaceuticals, cutting an estimated $46.1M.
  • EcoR1 Capital fully exited Legend Biotech in Q3 2026, selling an estimated $23.1M.
  • EcoR1 Capital's ten largest holdings make up 83% of its $2.25B portfolio in Q3 2026.
  • EcoR1 Capital opened 10 new positions and closed 7 in Q3 2026.
  • EcoR1 Capital's portfolio value rose 9.5% quarter-over-quarter to $2.25B.

Based on EcoR1 Capital's 13F filing for Q3 2026, filed 16 Nov 2026.